{"url_path":"/sec/uncy/8-k/2026-06-22/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-070316-index.html","accession_number":"0001213900-26-070316","cik":"0001766140","ticker":"UNCY","issuer_name":"Unicycive Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-070316-index.html","primary_entity_key":"0001766140","primary_entity_name":"Unicycive Therapeutics, Inc."},"word_count":270,"has_tables":true,"body_markdown":"**Item 5.07**\n**Submission of Matters to Vote of Security Holders**\n\n \n\nOn\nJune 19, 2025, Unicycive Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual\nMeeting”). A total of 14,964,159 shares of common stock, constituting a quorum, were represented in person or by valid proxies\nat the Annual Meeting. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting, as set forth\nin the Definitive Proxy Statement, filed with the Securities and Exchange Commission on April 30, 2026 are as follows:.\n\n \n\n*Proposal\n1*.  All of the three (3) nominees for director were elected to serve until the 2027 Annual Meeting of Stockholders or until\ntheir respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death.\nThe result of the votes to elect the three (3) directors was as follows:\n\n \n\nDirectors \nFor  \nWithhold  \nBroker\n\nNon-Votes \n\nDr. Shalabh Gupta \n 8,131,958  \n 173,587  \n 6,658,614 \n\nDr. Sandeep Laumas \n 7,696,050  \n 609,525  \n 6,658,584 \n\nD. Sarawati Kenkare-Mitra \n 7,510,434  \n 795,108  \n 6,658,617 \n\n \n\n*Proposal\n2.* The appointment of Grassi & Co. CPAs, P.C. as the Company’s independent registered public accounting firm for its\nfiscal year ended December 31, 2026 was ratified and approved by the stockholders by the votes set forth in the table below:\n\n \n\nFor  \nAgainst  \nAbstain  \nBroker Non Vote \n\n 14,667,242  \n 286,958  \n 9,928  \n 31 \n\n \n\n1\n\n \n\n \n\nSIGNATURE\n\n \n\nPursuant to the\nrequirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned\nhereunto duly authorized.\n\n \n\nDated:\nJune 22, 2026\n\n \n\n \nUNICYCIVE THERAPEUTICS, INC.\n\n \n \n\n \nBy: \n/s/ Shalabh\nGupta                      \n\n \n \nShalabh\nGupta\n\n \n \nChief Executive Officer\n\n \n\n2"}